Attitudes and Expectations regarding Dementia Risk Estimation among the General Population in Germany, Spain, and Switzerland.

Background: In recent years, research on risk estimation and early detection of Alzheimer’s disease (AD) advanced swiftly. Studies are investigating the likelihood of developing Alzheimer’s dementia (ADD), even during asymptomatic, preclinical, and prodromal stages of AD. Particular hope is pinned on blood‐based biomarkers as these are less invasive than other methods such as lumbar puncture and Positron Emission Tomography (PET)‐scan.

Omega‐6/Omega‐3 Ratio in Dementia Prevention ‐ Study Design and preliminary data of a feasibility study on lifestyle intervention.

Background: Alzheimer’s disease (AD) is the most common etiology of dementia. As the progression of the disease may be slowed down by disease‐modifying therapies, but not stopped, research identifying further therapeutic approaches is necessary. Due to the multifactorial etiology of AD, targeting modifiable risk factors for dementia, including diet, is a starting point for preventive interventions.

Preclinical Dementia Risk Estimation: Attitudes and Views of Relatives of Dementia Patients – The PreTAD‐Study.

Background: Due to further development of diagnostic methods of early‐stage diagnosis of Alzheimer’s disease (AD) and new disease‐modifying treatment options that require early diagnosis, a new focus on predictive and preventive medicine arises. With progress in AD dementia risk estimation, guidelines for counseling, considering individual aspects of those affected, are becoming more important. As part of the trinational project PreTAD (The Predictive Turn in Alzheimer’s Disease: Ethical, Clinical, Linguistic and Legal Aspects) anticipated effects of AD dementia risk estimation for first‐degree relatives of people with AD dementia are evaluated.

“I assume that my doctor will then guide me”: Attitudes and Expectations in the Context of Dementia Risk Estimation.

Background: Driven by (bio‐)medical and technical developments, advanced non‐invasive methods for estimating the risk of Alzheimer’s dementia (ADD) are increasingly emerging. In the future, such methods could eventually become available for individuals in asymptomatic and preclinical stages of Alzheimer’s disease (e.g.

Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients.

Introduction: Several recent research studies show high performance of blood biomarkers to identify Alzheimer's disease also in the pre-dementia mild cognitive impairment (MCI) stage, but data from the routine clinical care memory clinic setting are needed.

Methods: We examined plasma samples of 144 memory clinic patients, including dementia of Alzheimer type (DAT, n = 54), MCI (n = 57), and subjective cognitive decline (SCD, n = 33), who either presented as self-referrals or were referred by general practitioners or neurologists or psychiatrists. The plasma biomarkers, amyloid-beta42 (Aß42), amyloid-beta40 (Aß40), phospho-Tau181 (pTau181), total-tau (tTau), and neurofilament light (NFL), as well as different ratios, were measured using the ultrasensitive single molecule array (Simoa) immunoassay technology.